Introduction {#Sec1}
============

Cytotoxic chemotherapy suppresses the hematopoietic system affecting the host protective mechanisms. Among these hematological adverse effects, neutropenia is the most serious and usually the dose limiting toxicity \[[@CR1]\]. Several pharmacokinetic/pharmacodynamic (PK/PD) models have been developed to describe the time-course of myelosuppression \[[@CR2]--[@CR6]\]. One of the more widely used is a semi-mechanistic PK/PD model developed by Friberg et al. 2002 \[[@CR7]\]. This model describes the time course of myelosuppression after the administration of anticancer drugs by the use of system and drug related parameters. Consistency in its system-related parameters among a wide variety of anti-cancer agents and regimens has been demonstrated \[[@CR7]--[@CR16]\]. Recently, it has also been shown that this model could be used to predict the time-course of myelosuppression in humans, based on data obtained from experiments in rats \[[@CR17]\].

In anti-cancer drug development, the ability to predict the incidence of neutropenia in subsequent trials, based on the trial design, and a model conditioned on one or more previously performed studies would be valuable. It has been shown for example, that a two-stage design of Phase I trials, in which data from an initial trial is used to condition the PK/PD model and to predict a safe starting dose for the subsequent trials may be applied safely, and is able to reduce the number of patients included at dose levels below the recommended dose \[[@CR18]\]. As new data are accumulated during subsequent trials, model parameters can be updated to potentially provide less biased and more precise predictions of hematological toxicity.

Real data from the clinical development of two different anticancer drugs, diflomotecan and indisulam, were used in the current evaluation. These two drugs were given as anticancer monotherapy in their respective trials and therefore the neutropenia observed was a consequence of the administration of these drugs. Diflomotecan was the first homocamptothecin to enter clinical trials. Homocampotothecins are topoisomerase I inhibitors, that have greater ability to induce DNA cleavage mediated by topoisomerase I and a greater ability to stabilize topoisomerase I-DNA cleavable complexes when compared to the camptothecin-based topoisomerase I inhibitors \[[@CR19], [@CR20]\]. Indisulam is a cell cycle dependent anticancer drug that inhibits the cell-cycle at multiple checkpoints. The compound was shown to suppress the expression of cyclin E and phosphorylation of cyclin-dependent kinase 2 (CDK2), causing a disruption of the G1/S transition of the cell cycle \[[@CR21]\]. Both compounds have shown neutropenia as the major dose limiting toxicity \[[@CR22]--[@CR24]\].

The aim of this study was to evaluate the ability of the model for hematological toxicity developed by Friberg et al. 2002 \[[@CR7]\], to predict neutropenia early in the Phase I program of new anti-cancer agents, based on data gathered prior to the trial itself. The current investigation was performed assuming that Phase I development had occurred sequentially; i.e. trials investigating new regimens were only started once the current trial was completed. Model parameter estimates were obtained from: (a) data from each available trial independently, (b) pooled data from all clinical trials available or, (c) pooled data from the trials performed previously to the tested trial (Table [1](#Tab1){ref-type="table"}). Using the parameter estimates from each scenario, absolute neutrophil count (ANC) profiles expected for each trial were simulated. The simulated profiles from each scenario were then compared with the observed data, thus providing a comparison of predictions made from: (a) model parameters derived only from the trial in question, (b) model parameters derived from all trials, and (c) model parameters derived only from those trials preceding the trial in question. Table 1Data analyzed for each Scenario to predict the outcome of the respective studiesDiflomotecanStudyA. Current Study DataB. All dataC. Prior data1D1D1D + 2D + 3D + 4D + 5DNA2D2D1D + 2D + 3D + 4D + 5D1D3D3D1D + 2D + 3D + 4D + 5D1D + 2D4D4D1D + 2D + 3D + 4D + 5D1D + 2D + 3D5D5D1D + 2D + 3D + 4D + 5D1D + 2D + 3D + 4DIndisulamStudyA. Current Study DataB. All dataC. Prior data1I1I1I + 2I + 3I + 4INA2I2I1I + 2I + 3I + 4I1I3I3I1I + 2I + 3I + 4I1I + 2I4I4I1I + 2I + 3I + 4I1I + 2I + 3INA, Not applicable

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

Pharmacokinetic (PK) data and neutrophil counts from different clinical trials following administration of either diflomotecan or indisulam were available for the analysis. All participants provided written informed consent consistent with ICH-GCP (International conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use---Good Clinical Practice) and local legislation, once the nature and the intention of the investigation were fully explained. The studies were performed in accordance with the Declaration of Helsinki and were approved by the institutional review board of the ethics committee at each study site. The characteristics of the patient population from the five diflomotecan clinical trials and the four indisulam clinical trials used for the current analysis are presented in Table [2](#Tab2){ref-type="table"}. Table 2Schedules and patient characteristics**Diflomotecan***Characteristic*Study 1DStudy 2DStudy 3DStudy 4DStudy 5DSchedule^a^inf D 1inf D 1, 7, 14inf D1 oral D 14--18inf D 1--5inf D1 oral D 14--18Dose range1--12 mg/m^2^1--5 mg/m^2^0.9--2.1 mg0.5--1.5 mg0.9--2.1 mgCycle length3 weeks4 weeks3 weeks3 weeks3 weeksNeutrophil counts505252429607532*Demographics*^b^Number of patients2415243018Age (years)55 (34--73)52 (29--68)57 (34--71)57.5 (35--75)55.5 (33--70)Height (cm)169.5 (152--190)165 (155--180)173 (145--189)169.5 (155--188)169.5 (158--182)Weight (Kg)73 (42--90)64 (45--101)71 (51--101)74 (42--110)72 (48.5--123)Body surface area (m^2^)1.85 (1.36--2.17)1.71 (1.5--2.18)1.85 (1.59--2.25)1.87 (1.46--2.39)1.85 (1.5--2.4)Basal neutrophil count (x10^9^/L)5.88 (2.23--11.2)4.64 (2.6--15.22)5.12 (2.61--12.6)6.07 (2.6--16.65)5.19 (1.86--9.87)*Gender* Female46%67%38%40%44% Male54%33%62%60%56%      **Indisulam***Characteristic*Study 1IStudy 2IStudy 3IStudy 4ISchedule^a^1 × 2 hr inf5 × daily 2 hr inf4 × weekly 1 hr inf1 × 120 hr infDose range50--1,000 mg/m^2^10--200 mg/m^2^/day40--500 mg/m^2^/week6--200 mg/m^2^/dayCycle length3 weeks3 weeks6 weeks3 weeksNeutrophil counts211235453230*Demographics*^b^Number of patients40354226Age (years)53 (26--69)53 (27--73)59 (39--78)54 (26--64)Height (cm)168 (156--203)167 (152--191)170 (154--186)165 (149--178)Weight (kg)70 (43--106)64 (41.0--93.0)68 (43.4--122)62 (41.0--89.5)Body surface area (m^2^)1.80 (1.40--2.30)1.72 (1.34--2.06)1.82 (1.43--2.36)1.70 (1.37--2.06)Basal neutrophil count (x10^9^/L)5.25 (2.0--16.1)5.7 (1.78--17.9)4.9 (2.61--11.8)4.6 (1.7--12.2)*Gender*Female50%72.8%39.1%65.5%Male50%37.2%60.9%34.5%^a^ Administration schedule. Inf, infusion; D, day ^b^ Continuous demographic data is shown as median and range within parenthesis

### Diflomotecan {#Sec4}

Data from five Phase I clinical trials in advanced malignant tumors including a total of 111 patients were available. Patients were administered diflomotecan as intravenous infusion over 20 min on Day 1 (Study 1D) and on days 1, 2, 3, 4 and 5 (Study 4D) of a 21-day treatment cycle; and on Days 1, 7 and 14 of a 28-day treatment cycle (Study 2D). Patients in Studies 3D and 5D received an intravenous infusion on Day 1 followed by an oral administration given daily during Days 14 to 18. During the following cycles patients continued to receive an oral administration daily during five consecutive days every 21 days. The PK characteristics for intravenous and oral diflomotecan administrations have been described previously \[[@CR10], [@CR23]\].

Dose levels varied depending on the schedule and the type of administration (Table [2](#Tab2){ref-type="table"}). Neutrophil counts were measured in peripheral blood every 3 to 7 days during all treatment cycles, measuring a total of 2,325 counts for the five studies.

### Indisulam {#Sec5}

Indisulam has been investigated in a Phase I clinical program, administered in four different treatment schedules \[[@CR22], [@CR25]--[@CR27]\] from which PK and neutropenia data from a total of 150 patients were available. A population PK model has been developed previously to describe the disposition of indisulam in all four treatment schedules \[[@CR28]\].

In Study 1I, patients were administered indisulam as a single 2 h infusion every 3 weeks, and in Study 2I indisulam was given in 5 daily 2-hour infusion, also every 3 weeks. In trial 3I, the regimen consisted of a four times weekly 1 h infusion, repeated every 6 weeks, while study 4I consisted of a continuous 120-hour infusion every 3 weeks. Neutrophil counts were recorded at study entry and at least once a week and, when feasible, twice a week, up to 2 weeks after the last infusion of indisulam. When hematological toxicity occurred, sampling was performed more frequently according to local guidelines. A total of 1,129 neutrophil counts were measured for the four studies.

Data analysis {#Sec6}
-------------

The models were implemented in the non-linear mixed effects modeling software NONMEM version VI \[[@CR29]\], in which the First Order Conditional Estimation (FOCE) method with the option INTERACTION was used for parameter estimation. For each drug the modeling was performed sequentially using the population modeling approach. First, the PK model was applied to obtain the individual parameter estimates for each study, and using these estimates the time course of ANC was modeled.

**Pharmacokinetic model** The time course of the drug plasma concentrations for both anticancer agents was described previously by compartmental models parameterized in apparent volumes of distribution, and distribution and elimination clearances. The PK model for diflomotecan consisted of a three compartment model with a first order elimination \[[@CR10]\]. Linear and dose-independent kinetics with an oral absolute bioavailability of 72 ± 59% of the total administered dose have been reported for this drug \[[@CR23]\]. The indisulam PK model consisted of a three compartment model with saturable elimination from the central compartment \[[@CR28]\]. Additional information on diflomotecan and indisulam PK can be found in previous publications \[[@CR10], [@CR23], [@CR28]\].

**Semi-mechanistic model for absolute neutrophil count** The semi-mechanistic model for chemotherapy-induced myelosuppression (Fig. [1](#Fig1){ref-type="fig"}) previously published by Friberg et al., 2002 \[[@CR7]\] was fitted to the ANC vs. time data. This model consists of a system dependent and a drug dependent part. The system dependent part resembles in a simplified manner the underlying physiological processes determining the ANC in the circulation: (a) proliferation in a progenitor cell compartment, (b) maturation without proliferation, represented in the model by three transit compartments, (c) elimination from circulation, and (d) homeostatic regulation: i-iv can be described by the first order rate constant (k~prol~), the mean transit time (MTT), the first order rate constant of elimination from circulation (k~circ~), and the feedback parameter (γ). In addition, Circ~0~ represents ANC at baseline. In the original model $\documentclass[12pt]{minimal}
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### Model selection {#Sec7}

The minimum value of the objective function provided by NONMEM, approximately equal to -2xlog *likelihood* (*−2LL*), was used as a guide during the model development. For two nested models a decrease in 3.84 points in -2LL for an extra parameter was considered significant at the 5% level.

### Modeling strategy {#Sec8}

The modeling strategy consisted of two steps: (a) parameter estimation from the different datasets (see below), and (b) evaluation of the predictive ability of the model. Model parameter estimationIndependent analyses were performed for each drug and model parameter estimates were obtained for each of the following scenarios: Scenario A, data from each trial analyzed independently; Scenario B, pooled data from all available trials, and Scenario C, pooled data from the trials performed prior to the tested trial.In Scenario A, five different datasets were studied for diflomotecan (Studies 1D, 2D, 3D, 4D and 5D were analyzed independently), and for indisulam four datasets were studied (Studies 1I, 2I, 3I and 4I were analyzed independently). Scenario B corresponded to one analysis of pooled data of all the studies for each drug. In Scenario C, for both diflomotecan and indisulam, it was assumed that the trials were performed sequentially, i.e. from 1D to 5D, and from 1I to 4I, thereby leading to four and three steps to be evaluated, respectively. This approach allowed having for each trial, from 2D to 5D, for diflomotecan and from 2I to 4I for indisulam, a set of parameters representing each of the scenarios be to be studied. A total of nine different parameter estimate sets for diflomotecan and seven for indisulam were obtained (Table [1](#Tab1){ref-type="table"}).Evaluation of the prediction abilityThe ability of the parameter estimates (obtained from each of the three different scenarios) to describe the observed data was tested by simulating five hundred datasets having the same doses, administration schedules and design characteristics as the original dataset and performing numerical and visual \[[@CR31]\] predictive checks. Five hundred repetitions were used in the simulation exercise as the use of more repetitions did not relevantly alter the predicted outcome measures

### Numerical predictive checks {#Sec9}

The percentage of patients presenting neutropenia Grade 4 (%G4), and neutropenia Grade 3 or Grade 4 (%G3/4) were computed for each trial. Thereafter the overall mean and the 95% prediction intervals were calculated for each descriptor and compared to the same descriptors calculated from the raw data. This was then represented as a graphic, where %G4 or %G3/4 observed was plotted against the simulated %G4 or %G3/4 and its 95% prediction interval.

### Visual predictive checks {#Sec10}

The area covering the 95% confidence interval of the predicted median, the 5th and 95th percentiles of the prediction interval were plotted together with the median, and the 5th and 95th percentiles of the observed data. If the model described the data adequately the lines corresponding to the median, the 5th and 95th percentiles of the observed data would mainly fall in the area covering the 95% confidence interval.

For the analysis of simulated data, the R software (<http://cran.r-project.org>, version 2.6.0) was used. For the generation of visual predictive checks PsN (<http://psn.sourceforge.net/>) and Xpose version 4 (<http://xpose.sourceforge.net/>) were used.

Results {#Sec11}
=======

Diflomotecan {#Sec12}
------------

Model parameter estimationFor the nine datasets analyzed from the three explored scenarios the semi-mechanistic PK/PD model of neutropenia described the data adequately. Based on the minimum value of the objective function observations were considered best described by the reparameterized E~MAX~ model (*p *\< 0.01) except for the independent analysis of Studies 3D, 4D and 5D, where the drug effect was modeled using a linear function. The model parameter estimates are presented in Table [3](#Tab3){ref-type="table"}. The data supported the estimation of IPV in Circ~0~, MTT and slope (for linear models) or SLP (for the reparameterized E~MAX~ models). Inclusion of IPV in the feedback parameter was not statistically significant (*p *\> 0.05) System- and drug-related parameters were consistent across the studies. Precision in parameter estimates increased when the number of pooled patients analyzed per study increased.Evaluation of the prediction abilityTable 3Final model parameters (RSE%) for diflomotecanStudiesCirc~0~ (× 10^9^/L)IPV Circ~0~ (%)MTT (days)IPV MTT (%)Slope (mL/ng)IPV Slope (%)SLP (mL/ng)IPV SLP (%)EC~50~^a^E~MAX~γResidual error (%)^b^1D4.69 (10.5)36.7 (29)5.31 (8)31.1 (37)----0.817 (124)110 (94)7.556.17 (116)0.142 (8)61 (26)2D5.51 (15.7)50.3 (41)5.14 (14)10.9 (134)----1.35 (54)66 (64)4.786.46 (81)0.153 (20)45 (26)3D4.98 (8.9)34.8 (36)4.08 (14)23.3 (37)0.625 (20)50.2 (78)--------0.0855 (16)51 (24)4D6.57 (8.1)40 (31)4.53 (9)22.4 (49)1.06 (12)51 (42)--------0.096 (10)47 (20)5D5.27 (8.9)35.9 (37)5.06 (13)25.7 (46)0.823 (22)32 (193)--------0.0787 (13)42 (15)1D, 2D4.99 (8.4)42.3 (31)5.2 (6)36.1 (27)----1.11 (85)103 (62)4.945.49 (68)0.142 (6)56 (23)1D, 2D, 3D5.07 (6.2)38.6 (27)4.89 (7)26.3 (27)----1.02 (39)93 (39)5.225.33 (40)0.123 (10)55 (17)1D, 2D, 3D, 4D5.46 (5.04)39.4 (21)4.82 (5)25.1 (23)----1.13 (21)87 (26)4.785.40 (46)0.117 (8)53 (14)All5.37 (1.9)40 (19)4.91 (5)25.9 (21)----1.07 (17)82 (25)5.225.59 (27)0.113 (8)51 (12)Parameters are listed together with the coefficient of variation \[CV(%)\] in parenthesis. Circ~0~, basal ANC; MTT, maturation mean transit time; γ, feedback parameter; IPV, inter-patient variability expressed as CV (%). ^a^ Parameter calculated as EC~50~ = E~MAX~/SLP, ^b^ Implemented as additive error on the log-scale

### Numerical predictive checks {#Sec13}

In Fig. [2](#Fig2){ref-type="fig"} the mean values for the observed %G4 and %G3/4 neutropenia are shown against the mean %G4 and % G3/4 neutropenia calculated from the simulations. The observed value was within the prediction interval for the %G4 neutropenia for all evaluated situations, whereas for the %G3/4 neutropenia observations were outside the prediction interval in only one case i.e Study 4D in Scenario C (parameters estimates form previous studies were used in this case). For Study 4-D, in Scenario A and Scenario B the observations for %G3/4 were within the prediction intervals. However these two scenarios did not improve considerably the predictions when compared with Scenario C. Fig. 2Relation between the percentage of Grade 4 or Grade ≥ 3 observed versus the percentage predicted for diflomotecan (top row) and indisulam (bottom row).Symbols represent the relation between the observed percentage of patients developing neutropenia (Grade 4 or Grade ≥ 3) and the median of the percentage of patients developing neutropenia (Grade 4 or Grade ≥ 3) from simulations. Lines represent the 95% interval of the predicted descriptor

### Visual predictive checks {#Sec14}

The visual predictive checks presented in Fig. [3](#Fig3){ref-type="fig"} show that the description of data for each study was similar, independently of the set of model parameter estimates used for the simulations. For each study, the areas covering the 95% confidence interval of the predicted median, 5^th^ and 95^th^ percentiles were similar in each scenario. Fig. 3Neutrophil count (logarithm) vs time profile after the administration of diflomotecan for the different studies. Median (solid line) and 95th and 5th percentiles (dashed line) of the observations. Dark gray areas cover the 90% CI of the median and light grey areas cover the 90%CI of the 95th and the 5th percentiles of the simulated profiles

Indisulam {#Sec15}
---------

Model parameter estimationFor the seven datasets analyzed from the three explored scenarios, the E~MAX~ model did not provide significantly better fit, judged by the value of -2LL (*p *\> 0.05) and visual predictive checks. Therefore, only linear models were implemented and estimated. As in previous analyses with this compound \[[@CR32], [@CR33]\], the Circ~0~ parameter was not estimated, instead observed baseline ANCs were used, thereby assuming no error in baseline measurement. Different methods of incorporating baseline with measurement error are available \[[@CR34]\]. However when Circ0 was estimated, no relevant differences in predictions were observed and the VPCs for indisulam showed no apparent bias in the description of the baseline.Data supported the estimation of IPV in MTT and slope in all estimations. The feedback parameter, γ could be estimated with reasonable precision for all scenarios (RSE \<10%), and was between 0.116 and 0.190 (Table [4](#Tab4){ref-type="table"}). The data did not support the estimation of IPV in the feedback parameter. The system- and drug-related parameters were consistent across the studies and the corresponding estimates are listed in Table [4](#Tab4){ref-type="table"}.Evaluation of the prediction abilityTable 4Final model parameters (RSE%) for indisulamStudiesMTT (days)IPV MTT (%)Slope (mL/ng)IPV Slope (%)γResidual error (%)1I6.37 (2)27.6 (11)0.0242 (4)38.6 (26)0.167 (10)42 (14)2I7.11 (2)24.1 (18)0.0279 (5)55.2 (41)0.190 (7)34 (14)3I8.78 (1)30.6 (31)0.0176 (5)73 (28)0.152 (7)35 (1)4I5.06 (2)36.7 (22)0.0156 (6)110 (27)0.116 (7)43 (13)1I, 2I6.63 (1)26.8 (10)0.0252 (3)47.8 (23)0.177 (7)38 (10)1I, 2I, 3I7.26 (\<1)22.7 (9)0.0219 (\<1)55.0 (17)0.16 (1)37 (8)All studies6.90 (1)23.5 (9)0.0211 (1)59.0 (14)0.152 (2)38 (7)Parameters are listed together with the coefficient of variation \[CV(%)\] in parenthesis. MTT, maturation mean transit time; γ, feedback parameter; IPV, inter-patient variability expressed as CV (%)

### Numerical predictive checks {#Sec16}

In Fig. [2](#Fig2){ref-type="fig"} (bottom row) the mean values for the observed %G4 and %G3/4 neutropenia are shown against the mean %G4 and % G3/4 neutropenia calculated from the simulations for indisulam. Predicted %G4 and %G3/4 were best correlated with the observed when the model was conditioned on data from the specific study only, as all prediction intervals contained the observed percentages. Predictions based on all data were comparable to those obtained using previously accumulated data. The observed value for the %G4 and the %G3/4 neutropenia was outside the prediction interval for the %G4 neutropenia for Study 4I and for the %G3/4 of the Study 3-I, when conditioned on all or previous data. For these scenarios, the semi-physiological model was not able to describe schedule-dependency adequately, and the occurrence of toxicity would have been significantly underestimated or overestimated.

### Visual predictive checks {#Sec17}

For all studies, model fit was best when the model was conditioned on data from the specific study alone (Fig. [4](#Fig4){ref-type="fig"}). Model fit was not equally good for the cases where the model was fitted on all data. However, when fitted on only previously accumulated data, the model fit was similar to when all data were used. For Study 4I, studying the continuous infusion, model misspecification was present when the model was conditioned on all or previous data: the observed lower boundary of the 90% prediction interval was significantly lower than predicted in several consecutive bins. When conditioned on data from the study itself, the misspecification was less apparent. Fig. 4Neutrophil count (logarithm) vs time profile after the administration of indisulam for the different studies. Median (solid line), 95th and 5th percentiles (dashed line) of the observations. Dark gray areas cover the 95% CI of the median and light grey areas cover the 95% CI of the 95th and the 5th percentile of the simulated profiles

Discussion {#Sec18}
==========

The predictive ability of the PK/PD neutropenia model was evaluated for the anticancer drugs diflomotecan and indisulam. For both drugs simulations showed, visually and numerically, that a very similar description of data is achieved when data from all studies was used to condition the model, compared to the situation when data from the prior studies only was used. In most cases, such model performance also corresponded with the description of data provided by the model conditioned on the specific data of the study. Although each study had a different dose administration schedule, and a wide range of doses were studied throughout all the trials, the approach described here allowed for predictions based on model parameters obtained from prior trials. However an interesting fact seen for both of the drugs was that for Scenario C (use of previous data) the predictions did not turn out to be better as data were gained. For example the indisulam predictions for Study 4I based on previous data (i.e. Study 1I, 2I and 3I) were not better than predictions for Study 2I based only on Study 1I. This could be due to a schedule dependency in the development of toxicity that is not be captured by the model as Study 4I has a very different schedule (120 h infusion every 21 days) from the previous schedules tested. For diflomotecan a similar case was presented, where percentage of Grade 3/4 neutropenia for Studies 3D and 4D was not as well predicted as for Study 2I in Scenario C.

The semi-mechanistic model was successfully applied in all cases for both drugs, and in general precise parameters were provided. For diflomotecan in most of the cases an E~MAX~ model fitted data better than a linear model, except for the low dose studies where it was not possible to fit an E~MAX~ model. This was most likely due to the fact that these concentrations would correspond to the linear part of the response-concentration curve. In these linear models the difference for the slope parameter of 0.625 to 1.05 mL/ng (Studies 3D-5D) might be caused by the use of a reduced model due to the limited range of concentrations in those particular studies. However, when the E~MAX~ model was selected the range in the SLP and E~MAX~ parameters was smaller: 0.82--1.35 mL/ng and 5.33--6.46, respectively. In the manuscript by Trocóniz et al. \[[@CR10]\], data obtained after administration of higher doses of diflomotecan were analyzed. Based on the results provided by the current evaluation where the E~MAX~ model was identified as a better model than the linear one, the slope estimated in that case (0.144 mL/ng) should correspond to the upper (less steep) part of the effect vs concentration relationship.

Although system-related parameters obtained between studies and the two compounds were consistent, MTT estimates were in general higher for indisulam than for diflomotecan. A higher MTT estimate for indisulam in comparison with other drugs has been reported previously \[[@CR9]\].

The critical aspect in the current approach resides in the extrapolation capability of model parameter estimates obtained from a specific study to previously unstudied schedules. Therefore, it was of importance to study the model performance when using the model from data not including the current data of the study (Scenario C). In general, the visual predictive checks showed that ANC time profiles obtained for that case were similar to the ones for the cases where the current study data were taken into account (Scenarios A and B), indicating that parameter estimates could be extrapolated. However, and in particular for Study 4I, the description of the ANC time profile was considerably better for the case in which only data from the study was used to condition the model (Scenario A). The administration schedule of Study 4I consisted of a 5 day long continuous infusion; all the other studies analyzed had an infusion duration of 2 h or less. For this study, besides the large difference in administration schedule, also differences in the studied patient population may have inflated the differences in predictions. For instance, Study 4I had the lowest number of patients included, the highest percentage female patients, the lowest median weight, and the lowest median baseline ANCs of all four studies. If only data from a low number of patients is available, a critical assessment of predictive ability is difficult, since of those patients, only a low number of patients will develop grade 3/4 toxicities. Therefore, calculation of confidence intervals of observed ANC counts for such a study is sensitive to the inclusion of a few outlying patients.

However, for both drugs, using data of all studies (Scenario B) provided very similar predictions as using only data from prior studies (Scenario C). For indisulam, predicting neutropenia toxicity based on data from previous analyses had shown to be only moderately accurate. Prediction could however only be improved when data from the specific study were used.

The predictive performance of the three sets of parameters was also compared for their ability to predict clinically relevant descriptors, i.e. the incidence of Grade 3 or Grade 4 neutropenia. Therefore, the percentage of patients developing either Grade 4 neutropenia, or Grade 3 neutropenia or higher, was calculated for both the observed data and the simulated data.

It could be expected that the percentage of neutropenia for a specific study would be better predicted by the model conditioned on the data from that specific study. This means that the left panels in Fig. [2](#Fig2){ref-type="fig"} would present the best relationship between observed and predicted data. For some studies however, very similar predictions were seen regardless the set of model parameters used in the simulation (very similar predictions in all panels).

Predictions were more accurate for diflomotecan than for indisulam, especially for the % G4 neutropenia. A possible explanation for this result may be that in the diflomotecan trials a higher percentage of patients experienced neutropenia than in indisulam trials (Fig. [2](#Fig2){ref-type="fig"}), resulting in a better characterized dose response relationship.

Previous studies have already shown that estimated system-related model parameters are consistent across anti-cancer agents \[[@CR7]--[@CR16]\]. Furthermore, the predictive ability of this model has been also explored before in (i) a development of a tool that would be able to predict hematological toxicity in subsequent clinical trials, based on the study design and a model conditioned on one or more previously performed trials \[[@CR18]\], and also in (ii) a method for interspecies scaling where time course of myelosuppression was predicted based on rat data \[[@CR17]\], showing in both cases promising results. Further studies will have to verify if the same predictive ability applies to dose escalation studies.

Assuming that the Phase I development programs of studied drugs were performed sequentially, the current analysis explored the ability of the currently most used semi-mechanistic model of neutropenia to predict hematological effects in subsequent stages of the program, based on data gathered at earlier stages. The results presented in the current report are encouraging given the fact that for two drugs with different mechanism of action, and under very different dosing schedules, trials performed prior to a specific study gave a similar insight to the drug related-neutropenia as when using information from all studies retrospectively. It might be interesting to expand this research to other scenarios, such as the use of the PRIOR subroutine in NONMEM to introduce previous information, or the use of published system parameters in combination with drug related parameters estimated from previous studies.

This investigation provides further indication that modeling and simulation tools can be applied in the early stage of the drug development process to optimize future trials. Nevertheless, further studies should be done to determine the causes of the model-misspecification that led to the reduced predictive ability for some administration schedules.
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